ALIM Company Profile and Key Details
Alimera Sciences
Price Chart
Stock Price Today
Alimera Sciences, Inc. (ALIM) stock declined over -0.18%, trading at $5.54 on NASDAQ, down from the previous close of $5.55. The stock opened at $5.55, fluctuating between $5.53 and $5.56 in the recent session.
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2024 | 5.54 | 5.54 | 5.54 | 5.54 | 0 |
| Sep 17, 2024 | 5.54 | 5.54 | 5.54 | 5.54 | 0 |
| Sep 16, 2024 | 5.54 | 5.54 | 5.54 | 5.54 | 0 |
| Sep 13, 2024 | 5.55 | 5.56 | 5.53 | 5.54 | 2.68M |
| Sep 12, 2024 | 5.54 | 5.57 | 5.54 | 5.55 | 705.9K |
| Sep 11, 2024 | 5.53 | 5.56 | 5.52 | 5.53 | 2.11M |
| Sep 10, 2024 | 4.66 | 5.29 | 4.32 | 5.19 | 8.68M |
| Sep 09, 2024 | 5.56 | 5.57 | 5.53 | 5.55 | 1.59M |
| Sep 06, 2024 | 5.55 | 5.63 | 5.54 | 5.56 | 9.09M |
| Sep 05, 2024 | 5.56 | 5.56 | 5.53 | 5.54 | 1.19M |
| Sep 04, 2024 | 5.53 | 5.56 | 5.52 | 5.54 | 1.65M |
| Sep 03, 2024 | 5.55 | 5.56 | 5.51 | 5.52 | 1.03M |
| Aug 30, 2024 | 5.56 | 5.57 | 5.53 | 5.53 | 1.1M |
| Aug 29, 2024 | 5.57 | 5.58 | 5.53 | 5.54 | 2.26M |
| Aug 28, 2024 | 5.59 | 5.59 | 5.55 | 5.55 | 751.33K |
| Aug 27, 2024 | 5.59 | 5.60 | 5.58 | 5.59 | 268.4K |
| Aug 26, 2024 | 5.60 | 5.60 | 5.59 | 5.60 | 165.13K |
| Aug 23, 2024 | 5.59 | 5.60 | 5.58 | 5.59 | 210.6K |
| Aug 22, 2024 | 5.59 | 5.60 | 5.58 | 5.58 | 95.9K |
| Aug 21, 2024 | 5.60 | 5.60 | 5.58 | 5.59 | 65.7K |
Contact Details
About Company
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Company Information
| Employees | 154 |
| Beta | 1.25 |
| Sales or Revenue | $80.75M |
| 5Y Sales Change% | -0.686% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
Frequently Asked Questions
Non-Executive Chairman & Consultant
Mr. John Philip Jones
Chief Financial Officer
Christopher S. Visick
Vice President, Gen. Counsel & Sec.
Mr. Richard S. Eiswirth Jr.
Pres, Chief Executive Officer & Director
Dr. Philip Ashman Ph.D.
Chief Operating Officer & Senior Vice President of Commercial Operations - Europe
Mr. Russell L. Skibsted M.B.A.
Senior Vice President & Chief Financial Officer
Mr. David R. Holland
Co-Founder, Chief Marketing Officer and Senior Vice President of Corporation Communications & Managed Markets
Dr. David Dyer M.D.
Chief Retina Specialist
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep